<?xml version="1.0" encoding="UTF-8"?>
<feed xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns="http://www.w3.org/2005/Atom">
<title>vol. 26, no. 04</title>
<link href="http://sedici.unlp.edu.ar:80/handle/10915/211" rel="alternate"/>
<subtitle/>
<id>http://sedici.unlp.edu.ar:80/handle/10915/211</id>
<updated>2013-06-19T18:38:57Z</updated>
<dc:date>2013-06-19T18:38:57Z</dc:date>
<entry>
<title>La nueva farmacoterapia inorgánica: XVIII. Compuestos de lantánidos: XVIII. Lanthanide compounds</title>
<link href="http://sedici.unlp.edu.ar:80/handle/10915/7527" rel="alternate"/>
<author>
<name>Barán, Enrique José</name>
</author>
<id>http://sedici.unlp.edu.ar:80/handle/10915/7527</id>
<updated>2012-05-03T01:50:19Z</updated>
<published>2007-01-01T00:00:00Z</published>
<summary type="text">Revision
The new inorganic pharmacotherapy
Latin American Journal of Pharmacy; vol. 26, no. 4
Se presentan las características relevantes de la química de los lantánidos y su posible impacto&#13;
en sistemas biológicos. Luego se discuten diversos aspectos relacionados con la actividad farmacológica&#13;
de algunos de los elementos de este grupo, en particular su actividad antiemética, antimicrobiana y antitumoral.&#13;
Asimismo, se analiza el impacto del carbonato de lantano para el tratamiento de hiperfosfatemias y&#13;
de los nuevos complejos de gadolinio que se utilizan como agentes de contraste en estudios de resonancia&#13;
magnética nuclear. También se analiza el potencial de algunos radiofármacos conteniendo metales de este&#13;
grupo. Finalmente, se hacen breves comentarios sobre la toxicidad de estos elementos.; The relevant characteristics&#13;
of the chemistry of lanthanides and its possible impact on biological systems are presented. Next, various aspects&#13;
related to the pharmacological activity of some of the elements of this group are discussed, in particular&#13;
antiemetic, antimicrobial and antitumoral activity. Additionaly, the impact of lanthanum carbonate for the treatment&#13;
of hyperphosphatemias and the new gadolinium complexes, used as contrasting agents in nuclear magnetic&#13;
resonance studies, are also analyzed. The potential of different radiopharmaceuticals containing metals of this&#13;
group is also discussed. Finally, brief comments about the toxicity of these elements are made.
</summary>
<dc:date>2007-01-01T00:00:00Z</dc:date>
<dc:description>Se presentan las características relevantes de la química de los lantánidos y su posible impacto&#13;
en sistemas biológicos. Luego se discuten diversos aspectos relacionados con la actividad farmacológica&#13;
de algunos de los elementos de este grupo, en particular su actividad antiemética, antimicrobiana y antitumoral.&#13;
Asimismo, se analiza el impacto del carbonato de lantano para el tratamiento de hiperfosfatemias y&#13;
de los nuevos complejos de gadolinio que se utilizan como agentes de contraste en estudios de resonancia&#13;
magnética nuclear. También se analiza el potencial de algunos radiofármacos conteniendo metales de este&#13;
grupo. Finalmente, se hacen breves comentarios sobre la toxicidad de estos elementos.

The relevant characteristics&#13;
of the chemistry of lanthanides and its possible impact on biological systems are presented. Next, various aspects&#13;
related to the pharmacological activity of some of the elements of this group are discussed, in particular&#13;
antiemetic, antimicrobial and antitumoral activity. Additionaly, the impact of lanthanum carbonate for the treatment&#13;
of hyperphosphatemias and the new gadolinium complexes, used as contrasting agents in nuclear magnetic&#13;
resonance studies, are also analyzed. The potential of different radiopharmaceuticals containing metals of this&#13;
group is also discussed. Finally, brief comments about the toxicity of these elements are made.</dc:description>
</entry>
<entry>
<title>Espécies de senecio na medicina popular da América Latina e toxicidade relacionada a sua utilização</title>
<link href="http://sedici.unlp.edu.ar:80/handle/10915/7526" rel="alternate"/>
<author>
<name>Bolzan, Aline A.</name>
</author>
<author>
<name>Silva, Chana M.</name>
</author>
<author>
<name>Francescato, Leandro N.</name>
</author>
<author>
<name>Murari, Anelise L.</name>
</author>
<author>
<name>Silva, Glória N. S.</name>
</author>
<author>
<name>Heldwein, Clarissa G.</name>
</author>
<author>
<name>Heinzmann, Berta Maria</name>
</author>
<id>http://sedici.unlp.edu.ar:80/handle/10915/7526</id>
<updated>2012-05-03T01:50:19Z</updated>
<published>2007-01-01T00:00:00Z</published>
<summary type="text">Revision
Senecio species used as medicinal in Latin America and toxicity associated to their utilization
Latin American Journal of Pharmacy; vol. 26, no. 4
Este trabalho apresenta uma revisão sobre as espécies de Senecio utilizadas na medicina popular na América Latina. São citadas 46 plantas, com as indicações de uso e o respectivo país. Também são apresentados os aspectos envolvidos na toxicidade destas espécies, de responsabilidade dos alcalóides pirrolizidínicos. São relatados os casos de intoxicação em humanos, sendo discutidas estratégias para prevenílas.; This work shows a review of the Senecio species used in the folk medicine of Latin America. 46 plants are mentioned with their medicinal uses and their corresponding countries. The aspects involved in the toxicity of these plants caused by the presence of pyrrolizidine alkaloids, are also presented. Cases of human toxicity are reported, and strategies to avoid them are discussed.
</summary>
<dc:date>2007-01-01T00:00:00Z</dc:date>
<dc:description>Este trabalho apresenta uma revisão sobre as espécies de Senecio utilizadas na medicina popular na América Latina. São citadas 46 plantas, com as indicações de uso e o respectivo país. Também são apresentados os aspectos envolvidos na toxicidade destas espécies, de responsabilidade dos alcalóides pirrolizidínicos. São relatados os casos de intoxicação em humanos, sendo discutidas estratégias para prevenílas.

This work shows a review of the Senecio species used in the folk medicine of Latin America. 46 plants are mentioned with their medicinal uses and their corresponding countries. The aspects involved in the toxicity of these plants caused by the presence of pyrrolizidine alkaloids, are also presented. Cases of human toxicity are reported, and strategies to avoid them are discussed.</dc:description>
</entry>
<entry>
<title>Epibatidina: uma breve revisão</title>
<link href="http://sedici.unlp.edu.ar:80/handle/10915/7525" rel="alternate"/>
<author>
<name>Barcellos Falkenberg, Miriam de</name>
</author>
<author>
<name>Albino Pereira, Pablo</name>
</author>
<id>http://sedici.unlp.edu.ar:80/handle/10915/7525</id>
<updated>2012-05-03T01:50:19Z</updated>
<published>2007-01-01T00:00:00Z</published>
<summary type="text">Articulo
Epibatidine: a short review
Latin American Journal of Pharmacy; vol. 26, no. 4
O presente artigo revisa a história do alcalóide epibatidina, isolado da pele de sapos do gênero&#13;
Epipedobates, encontrados na América Central e do Sul. A descoberta, a elucidação estrutural e a investigação&#13;
de aspectos farmacológicos da substância, que apresentou elevada potência analgésica e um mecanismo&#13;
de ação até então desconhecido, são aqui apresentadas, bem como as tentativas de desenvolver fármacos&#13;
analgésicos a partir da estrutura protótipo.; The present article revises the history of epibatidine, an alkaloid&#13;
which was isolated from the skin of Epipedobates tricolor, a frog found in jungles of Central and South America.&#13;
We present the discovery context, the structural elucidation and the pharmacological properties of this natural&#13;
product, which showed high analgesic potency and a new mechanism of action. The efforts to develop new analgesic&#13;
drugs from epibatidine as a lead compound are also described.
</summary>
<dc:date>2007-01-01T00:00:00Z</dc:date>
<dc:description>O presente artigo revisa a história do alcalóide epibatidina, isolado da pele de sapos do gênero&#13;
Epipedobates, encontrados na América Central e do Sul. A descoberta, a elucidação estrutural e a investigação&#13;
de aspectos farmacológicos da substância, que apresentou elevada potência analgésica e um mecanismo&#13;
de ação até então desconhecido, são aqui apresentadas, bem como as tentativas de desenvolver fármacos&#13;
analgésicos a partir da estrutura protótipo.

The present article revises the history of epibatidine, an alkaloid&#13;
which was isolated from the skin of Epipedobates tricolor, a frog found in jungles of Central and South America.&#13;
We present the discovery context, the structural elucidation and the pharmacological properties of this natural&#13;
product, which showed high analgesic potency and a new mechanism of action. The efforts to develop new analgesic&#13;
drugs from epibatidine as a lead compound are also described.</dc:description>
</entry>
<entry>
<title>Evaluación del cumplimiento terapéutico en el tratamiento o profilaxis de la tuberculosis</title>
<link href="http://sedici.unlp.edu.ar:80/handle/10915/7524" rel="alternate"/>
<author>
<name>Bay, M. Rosa</name>
</author>
<author>
<name>González, Gladys</name>
</author>
<author>
<name>Pedrini, Marcela</name>
</author>
<author>
<name>García Sarubbio, Marisol</name>
</author>
<author>
<name>Arrieta, Marisa</name>
</author>
<author>
<name>Zoco, Eliana</name>
</author>
<author>
<name>Destefanis, Andrés</name>
</author>
<author>
<name>González, Patricia</name>
</author>
<id>http://sedici.unlp.edu.ar:80/handle/10915/7524</id>
<updated>2012-05-03T01:50:19Z</updated>
<published>2007-01-01T00:00:00Z</published>
<summary type="text">Articulo
Evaluation of the therapeutic fulfilment in the treatment or profilaxis of tuberculosis
Latin American Journal of Pharmacy; vol. 26, no. 4
En el presente trabajo se evaluaron los registros existentes en el Servicio de Farmacia del&#13;
Hospital Zonal General de Agudos San Roque (M.B. Gonnet, Argentina) de los pacientes diagnosticados&#13;
con tuberculosis y los convivientes de dichos pacientes que retiraron la medicación de dicho servicio en el&#13;
período Enero de 2001 a Abril de 2004. Se trabajó con 2 grupos, quienes no recibieron Atención Farmacéutica&#13;
(Etapa 1) y quienes sí la recibieron (Etapa 2). Del presente trabajo se concluyó que existe una tendencia&#13;
hacia la mejora en el cumplimiento de los pacientes que recibieron Atención Farmacéutica respecto&#13;
de los que no la recibieron.; The aim&#13;
of this study was to evaluate the records existing in the Pharmacy Service of the Hospital Zonal General de Agudos&#13;
San Roque (M.B. Gonnet, Argentina) of patients suffering tuberculosis and the persons living together with&#13;
them who received the medicaments from the Service during January 2001 to April 2004. Two groups were defined:&#13;
those who did not receive Pharmaceutical Care (stage 1) and those who received Pharmaceutical Care&#13;
(Stage 2).
</summary>
<dc:date>2007-01-01T00:00:00Z</dc:date>
<dc:description>En el presente trabajo se evaluaron los registros existentes en el Servicio de Farmacia del&#13;
Hospital Zonal General de Agudos San Roque (M.B. Gonnet, Argentina) de los pacientes diagnosticados&#13;
con tuberculosis y los convivientes de dichos pacientes que retiraron la medicación de dicho servicio en el&#13;
período Enero de 2001 a Abril de 2004. Se trabajó con 2 grupos, quienes no recibieron Atención Farmacéutica&#13;
(Etapa 1) y quienes sí la recibieron (Etapa 2). Del presente trabajo se concluyó que existe una tendencia&#13;
hacia la mejora en el cumplimiento de los pacientes que recibieron Atención Farmacéutica respecto&#13;
de los que no la recibieron.

The aim&#13;
of this study was to evaluate the records existing in the Pharmacy Service of the Hospital Zonal General de Agudos&#13;
San Roque (M.B. Gonnet, Argentina) of patients suffering tuberculosis and the persons living together with&#13;
them who received the medicaments from the Service during January 2001 to April 2004. Two groups were defined:&#13;
those who did not receive Pharmaceutical Care (stage 1) and those who received Pharmaceutical Care&#13;
(Stage 2).</dc:description>
</entry>
<entry>
<title>Estudo da utilização de plantas medicinais e medicamentos em um município do sul do Brasil</title>
<link href="http://sedici.unlp.edu.ar:80/handle/10915/7523" rel="alternate"/>
<author>
<name>Hepp Schwambach, Karin</name>
</author>
<author>
<name>Alves Amador, Tânia</name>
</author>
<id>http://sedici.unlp.edu.ar:80/handle/10915/7523</id>
<updated>2012-05-03T01:50:19Z</updated>
<published>2007-01-01T00:00:00Z</published>
<summary type="text">Articulo
Study of medicinal plants and medicines use in the south of Brazil
Latin American Journal of Pharmacy; vol. 26, no. 4
A tomada de decisão para o uso de plantas medicinais pode advir de uma somatória de fatores&#13;
como circunstâncias históricas e culturais, socioeconômicas e da percepção de segurança de produtos naturais.&#13;
Esta prática pode ter influência na aplicação de outros recursos terapêuticos da medicina convencional.&#13;
O objetivo desse estudo é descrever o perfil de consumo de plantas medicinais e medicamentos na&#13;
população de um município da região Sul do Brasil. A pesquisa seguiu um modelo transversal descritivo,&#13;
utilizando um questionário semi-estruturado na coleta de dados. Foram realizadas e analisadas 196 entrevistas&#13;
domiciliares. Dentre os entrevistados, 87,2% eram do sexo feminino, com idade média de 44,4 ±&#13;
13,86 anos. O uso de plantas medicinais foi relatado por 92,9% dos entrevistados, com média de 4,8 ± 3,7&#13;
plantas por pessoa. Para a maioria dos respondentes (74,8%) a informação sobre o uso das plantas medicinais&#13;
está baseada no conhecimento tradicional, sendo usadas principalmente para tratar sintomas de condições&#13;
relacionadas ao trato gastrintestinal, condições relacionadas ao sistema respiratório ou simplesmente&#13;
como bebida. Quanto à utilização de medicamentos, 37,8% dos entrevistados relataram que utilizam&#13;
medicamentos sempre, 31,1% quando não se sentem bem e 8,7% somente quando consultam o médico. Os&#13;
resultados iniciais reforçam a necessidade de pesquisas com critérios que levem em consideração o padrão&#13;
de uso entre grupos específicos de pacientes, como portadores de doenças crônicas, relatos de reações adversas,&#13;
efeitos em longo prazo, ou que avaliem os riscos e benefícios da utilização das plantas medicinais&#13;
pela população e estratégias para a promoção do uso racional destes recursos terapêuticos.; Decision-making to the use&#13;
of medicinal plants may come from a sommatory of factors as cultural and historical circumstances, social and&#13;
economic aspects and also the perception of the safety of natural products. This practice can influence the application&#13;
of other therapeutic recourses of conventional medicine. The aim of this study is to describe the profile of&#13;
consumption of medicinal plants and medicines in a population in the South region district. The research followed&#13;
a cross-seccional descriptive pattern, using a semi-structured questionary to collect the data. Were analysed&#13;
196 domiciliar interviews. Among the interviewers, 87.2% were female, on avarage age 44,4 ± 13.86 years&#13;
old. The use of the medicinal plants was reported by 92,9% interviewers, on avarage of 4.8 ± 3.7 plants per person.&#13;
For the most of them (74.8%), the information about the use of medicinal plants is based on traditional&#13;
knowledge, being used mainly to treat symptoms of the gastrointestinal tract, conditions related to the respiratory&#13;
system or simply as beverage. In relation to the use of medicines, 37.8% of the interviewers related that always&#13;
use the medicines, 31,1% use them, when they do not feel well, and 8.7% only when see the doctor. The initial&#13;
results reinforce the research necessity in criterions which consider the standard use among specific groups of patients,&#13;
as chronic disease porters, adverse reactions references, long therm effects, or that evaluate the risks and&#13;
the benefits of medicinal plants used by the population and strategies to promote the rational use of these therapeutic&#13;
recourses.
</summary>
<dc:date>2007-01-01T00:00:00Z</dc:date>
<dc:description>A tomada de decisão para o uso de plantas medicinais pode advir de uma somatória de fatores&#13;
como circunstâncias históricas e culturais, socioeconômicas e da percepção de segurança de produtos naturais.&#13;
Esta prática pode ter influência na aplicação de outros recursos terapêuticos da medicina convencional.&#13;
O objetivo desse estudo é descrever o perfil de consumo de plantas medicinais e medicamentos na&#13;
população de um município da região Sul do Brasil. A pesquisa seguiu um modelo transversal descritivo,&#13;
utilizando um questionário semi-estruturado na coleta de dados. Foram realizadas e analisadas 196 entrevistas&#13;
domiciliares. Dentre os entrevistados, 87,2% eram do sexo feminino, com idade média de 44,4 ±&#13;
13,86 anos. O uso de plantas medicinais foi relatado por 92,9% dos entrevistados, com média de 4,8 ± 3,7&#13;
plantas por pessoa. Para a maioria dos respondentes (74,8%) a informação sobre o uso das plantas medicinais&#13;
está baseada no conhecimento tradicional, sendo usadas principalmente para tratar sintomas de condições&#13;
relacionadas ao trato gastrintestinal, condições relacionadas ao sistema respiratório ou simplesmente&#13;
como bebida. Quanto à utilização de medicamentos, 37,8% dos entrevistados relataram que utilizam&#13;
medicamentos sempre, 31,1% quando não se sentem bem e 8,7% somente quando consultam o médico. Os&#13;
resultados iniciais reforçam a necessidade de pesquisas com critérios que levem em consideração o padrão&#13;
de uso entre grupos específicos de pacientes, como portadores de doenças crônicas, relatos de reações adversas,&#13;
efeitos em longo prazo, ou que avaliem os riscos e benefícios da utilização das plantas medicinais&#13;
pela população e estratégias para a promoção do uso racional destes recursos terapêuticos.

Decision-making to the use&#13;
of medicinal plants may come from a sommatory of factors as cultural and historical circumstances, social and&#13;
economic aspects and also the perception of the safety of natural products. This practice can influence the application&#13;
of other therapeutic recourses of conventional medicine. The aim of this study is to describe the profile of&#13;
consumption of medicinal plants and medicines in a population in the South region district. The research followed&#13;
a cross-seccional descriptive pattern, using a semi-structured questionary to collect the data. Were analysed&#13;
196 domiciliar interviews. Among the interviewers, 87.2% were female, on avarage age 44,4 ± 13.86 years&#13;
old. The use of the medicinal plants was reported by 92,9% interviewers, on avarage of 4.8 ± 3.7 plants per person.&#13;
For the most of them (74.8%), the information about the use of medicinal plants is based on traditional&#13;
knowledge, being used mainly to treat symptoms of the gastrointestinal tract, conditions related to the respiratory&#13;
system or simply as beverage. In relation to the use of medicines, 37.8% of the interviewers related that always&#13;
use the medicines, 31,1% use them, when they do not feel well, and 8.7% only when see the doctor. The initial&#13;
results reinforce the research necessity in criterions which consider the standard use among specific groups of patients,&#13;
as chronic disease porters, adverse reactions references, long therm effects, or that evaluate the risks and&#13;
the benefits of medicinal plants used by the population and strategies to promote the rational use of these therapeutic&#13;
recourses.</dc:description>
</entry>
<entry>
<title>Avaliação de interações medicamentosas potenciais em prescrições médicas do Hospital das Clínicas da Universidade Federal de Minas Gerais (Brasil)</title>
<link href="http://sedici.unlp.edu.ar:80/handle/10915/7522" rel="alternate"/>
<author>
<name>Moura, Cristiano S.</name>
</author>
<author>
<name>Ribeiro, Andréia</name>
</author>
<author>
<name>Starling Magalhaes, Sérgia María</name>
</author>
<id>http://sedici.unlp.edu.ar:80/handle/10915/7522</id>
<updated>2012-05-03T01:50:19Z</updated>
<published>2007-01-01T00:00:00Z</published>
<summary type="text">Articulo
Potential drug interactions in medical prescriptions from a Brazilian University Hospital
Latin American Journal of Pharmacy; vol. 26, no. 4
Pacientes em politerapia são particularmente expostos a interações medicamentosas que podem&#13;
levar a reação adversa a medicamentos ou falha terapêutica. O estudo objetivou avaliar a freqüência&#13;
de interações medicamentosas potenciais envolvendo psicofármacos em prescrições de um hospital universitário.&#13;
Foram avaliadas 452 prescrições, selecionadas sistematicamente dos registros do hospital. Em&#13;
22,0% das prescrições havia pelo menos uma interação. Destas, 47% eram de relevância clínica. Foi encontrada&#13;
associação positiva entre politerapia e ocorrência de interações. Este estudo mostrou que interações&#13;
medicamentosas são freqüentes em ambiente hospitalar. A adoção de medidas, como a utilização de&#13;
sistemas eletrônicos de detecção de interações pode contribuir para a minimização destes eventos.; Patients&#13;
receiving polytherapy are particularly exposed to drug-drug interactions (DDI's), a situation that may lead&#13;
to adverse drug reaction or fail in the treatment. The objective of this study was to evaluate the frequency of drug&#13;
interactions involving CNS active drugs in prescriptions from a Brazilian university hospital. A set of 452 prescriptions&#13;
were systematically selected from the hospital database records. The rate of prescriptions with at least&#13;
one potential drug interaction was 22%. Of these, 47% were clinically significant. A positive association between&#13;
polytherapy and drug interactions was found (P = 0,00). This study showed that potential DDI's are frequent in&#13;
hospital settings. Safeguards, such as computerized drug interaction detection systems, need to be introduced to&#13;
prevent the occurrence of these events.
</summary>
<dc:date>2007-01-01T00:00:00Z</dc:date>
<dc:description>Pacientes em politerapia são particularmente expostos a interações medicamentosas que podem&#13;
levar a reação adversa a medicamentos ou falha terapêutica. O estudo objetivou avaliar a freqüência&#13;
de interações medicamentosas potenciais envolvendo psicofármacos em prescrições de um hospital universitário.&#13;
Foram avaliadas 452 prescrições, selecionadas sistematicamente dos registros do hospital. Em&#13;
22,0% das prescrições havia pelo menos uma interação. Destas, 47% eram de relevância clínica. Foi encontrada&#13;
associação positiva entre politerapia e ocorrência de interações. Este estudo mostrou que interações&#13;
medicamentosas são freqüentes em ambiente hospitalar. A adoção de medidas, como a utilização de&#13;
sistemas eletrônicos de detecção de interações pode contribuir para a minimização destes eventos.

Patients&#13;
receiving polytherapy are particularly exposed to drug-drug interactions (DDI's), a situation that may lead&#13;
to adverse drug reaction or fail in the treatment. The objective of this study was to evaluate the frequency of drug&#13;
interactions involving CNS active drugs in prescriptions from a Brazilian university hospital. A set of 452 prescriptions&#13;
were systematically selected from the hospital database records. The rate of prescriptions with at least&#13;
one potential drug interaction was 22%. Of these, 47% were clinically significant. A positive association between&#13;
polytherapy and drug interactions was found (P = 0,00). This study showed that potential DDI's are frequent in&#13;
hospital settings. Safeguards, such as computerized drug interaction detection systems, need to be introduced to&#13;
prevent the occurrence of these events.</dc:description>
</entry>
<entry>
<title>Implementación de un programa de atención farmacéutica en farmacias comunitarias para la detección de la hipertensión arterial y su seguimiento farmacoterapéutico</title>
<link href="http://sedici.unlp.edu.ar:80/handle/10915/7521" rel="alternate"/>
<author>
<name>Lugo de Ortellado, Gladys</name>
</author>
<author>
<name>Rodríguez de Bittner, Magaly</name>
</author>
<author>
<name>Chávez G., Hernán</name>
</author>
<author>
<name>Pérez, Samuel</name>
</author>
<id>http://sedici.unlp.edu.ar:80/handle/10915/7521</id>
<updated>2012-05-03T01:50:20Z</updated>
<published>2008-01-01T00:00:00Z</published>
<summary type="text">Articulo
Implementation of a pharmaceutical care program for the detection of hypertension and drug therapy to be followed up in community pharmacies
Latin American Journal of Pharmacy; vol. 26, no. 4
Este trabajo tiene el propósito de valorar el efecto de un Programa de Atención Farmacéutica&#13;
en Paraguay, para lo cual se realizó un estudio prospectivo controlado, dirigido a pacientes hipertensos, en&#13;
farmacias comunitarias. Al final del estudio, el promedio de presión arterial sistólica disminuyó en el grupo&#13;
intervenido, de 147 a 128 mm de Hg, mientras que en el control se observó un aumento de 148 a 154&#13;
mm de Hg; la presión arterial diastólica en el grupo intervenido de 89 a 83 mm de Hg; no se observaron&#13;
variaciones en el grupo control en esta variable. Al inicio del programa el 45% de pacientes clasificados&#13;
dentro del estadio II de hipertensión disminuyeron a 9%. Mientras que en el grupo control se mantuvieron&#13;
en los estadios iniciales y algunos alcanzaron estadios mayores. El 93% de los problemas relacionados&#13;
con los medicamentos detectados fueron resueltos. Los resultados estadísticamente evaluados, con valores&#13;
de p siempre menores a 5%, demuestran el valor de un programa de Atención Farmacéutica en las farmacias&#13;
comunitarias.; This work evaluates the effectiveness of a program of&#13;
Pharmaceutical Care in Paraguay in a controlled prospective study directed to hypertensive patients in community&#13;
pharmacies. At the culmination of the study the mean systolic pressure was down from 147 to 128 mm Hg in&#13;
the target population, while in the control group the mean systolic pressure went up from 148 to 154 mm Hg. The&#13;
mean diastolic pressure went down from 89 to 83 mm Hg in the intervened group while no change was observed&#13;
in the mean diastolic pressure of the control group. Of the 45% of the patients classified at stage II hypertension&#13;
at the beginning of the study, only 9% remained in that stage at the end of it, while the control group either kept&#13;
or went up to the next classification stage. Ninety three percent of the problems detected that were related to the&#13;
medicines were solved. These results, statistically evaluated, with p values always below 5% demonstrate the importance&#13;
of a program of pharmaceutical care in community pharmacies.
</summary>
<dc:date>2008-01-01T00:00:00Z</dc:date>
<dc:description>Este trabajo tiene el propósito de valorar el efecto de un Programa de Atención Farmacéutica&#13;
en Paraguay, para lo cual se realizó un estudio prospectivo controlado, dirigido a pacientes hipertensos, en&#13;
farmacias comunitarias. Al final del estudio, el promedio de presión arterial sistólica disminuyó en el grupo&#13;
intervenido, de 147 a 128 mm de Hg, mientras que en el control se observó un aumento de 148 a 154&#13;
mm de Hg; la presión arterial diastólica en el grupo intervenido de 89 a 83 mm de Hg; no se observaron&#13;
variaciones en el grupo control en esta variable. Al inicio del programa el 45% de pacientes clasificados&#13;
dentro del estadio II de hipertensión disminuyeron a 9%. Mientras que en el grupo control se mantuvieron&#13;
en los estadios iniciales y algunos alcanzaron estadios mayores. El 93% de los problemas relacionados&#13;
con los medicamentos detectados fueron resueltos. Los resultados estadísticamente evaluados, con valores&#13;
de p siempre menores a 5%, demuestran el valor de un programa de Atención Farmacéutica en las farmacias&#13;
comunitarias.

This work evaluates the effectiveness of a program of&#13;
Pharmaceutical Care in Paraguay in a controlled prospective study directed to hypertensive patients in community&#13;
pharmacies. At the culmination of the study the mean systolic pressure was down from 147 to 128 mm Hg in&#13;
the target population, while in the control group the mean systolic pressure went up from 148 to 154 mm Hg. The&#13;
mean diastolic pressure went down from 89 to 83 mm Hg in the intervened group while no change was observed&#13;
in the mean diastolic pressure of the control group. Of the 45% of the patients classified at stage II hypertension&#13;
at the beginning of the study, only 9% remained in that stage at the end of it, while the control group either kept&#13;
or went up to the next classification stage. Ninety three percent of the problems detected that were related to the&#13;
medicines were solved. These results, statistically evaluated, with p values always below 5% demonstrate the importance&#13;
of a program of pharmaceutical care in community pharmacies.</dc:description>
</entry>
<entry>
<title>Política de prescripción de antirretrovirales en Argentina: adhesión a las recomendaciones del Programa Nacional</title>
<link href="http://sedici.unlp.edu.ar:80/handle/10915/7520" rel="alternate"/>
<author>
<name>Palchik, Valeria</name>
</author>
<author>
<name>Acevedo, Eric</name>
</author>
<author>
<name>Maiztegui, María Soledad</name>
</author>
<author>
<name>Tagliatori, Romina</name>
</author>
<author>
<name>Colautti, Marisel</name>
</author>
<id>http://sedici.unlp.edu.ar:80/handle/10915/7520</id>
<updated>2012-05-03T01:50:20Z</updated>
<published>2007-01-01T00:00:00Z</published>
<summary type="text">Articulo
Antirretrovirals prescription policy in Argentina: adhesion to the National Program recommendations
Latin American Journal of Pharmacy; vol. 26, no. 4
El Programa Nacional VIH/SIDA de Argentina incorporó nuevos antirretrovirales (ARV) dando lugar a terapias combinadas. El objetivo del trabajo es comparar la adhesión de los tratamientos prescriptos a las recomendaciones del Programa Nacional. Se categorizan los tratamientos según el mecanismo de acción de los ARV en dos efectores de Rosario. Se obtienen 20 categorías y 92 subcategorías; aproximadamente el 73% de los tratamientos prescriptos están recomendados y se distribuyen entre dos de las categorías definidas anteriormente. El progreso científico y tecnológico posibilita esta gran variabilidad de ARV y sus combinaciones. La diversidad de tratamientos observados está asociada a múltiples factores que involucran características del paciente y criterio del prescriptor.; The new antirretroviral (ARV) medicines recognized by the National HIV Program of Argentine allow the treatment with combined therapies. The objective of this work is to compare the prescribed ARV treatments with the National Program recommendations. The ARV treatments applied in two hospitals of the city of Rosario were categorized based in the action mechanism of drugs. Twenty categories and ninety two sub-categories were obtained. Seventy three percent of prescriptions treatments are recommendable and are included between two of the categories before defined. The scientific and technology progress make possible a grand variability of ARV and its possible combinations. Multiple factors are associated with the diversity of treatments, including patients' characteristics, and prescriptors criteria.
</summary>
<dc:date>2007-01-01T00:00:00Z</dc:date>
<dc:description>El Programa Nacional VIH/SIDA de Argentina incorporó nuevos antirretrovirales (ARV) dando lugar a terapias combinadas. El objetivo del trabajo es comparar la adhesión de los tratamientos prescriptos a las recomendaciones del Programa Nacional. Se categorizan los tratamientos según el mecanismo de acción de los ARV en dos efectores de Rosario. Se obtienen 20 categorías y 92 subcategorías; aproximadamente el 73% de los tratamientos prescriptos están recomendados y se distribuyen entre dos de las categorías definidas anteriormente. El progreso científico y tecnológico posibilita esta gran variabilidad de ARV y sus combinaciones. La diversidad de tratamientos observados está asociada a múltiples factores que involucran características del paciente y criterio del prescriptor.

The new antirretroviral (ARV) medicines recognized by the National HIV Program of Argentine allow the treatment with combined therapies. The objective of this work is to compare the prescribed ARV treatments with the National Program recommendations. The ARV treatments applied in two hospitals of the city of Rosario were categorized based in the action mechanism of drugs. Twenty categories and ninety two sub-categories were obtained. Seventy three percent of prescriptions treatments are recommendable and are included between two of the categories before defined. The scientific and technology progress make possible a grand variability of ARV and its possible combinations. Multiple factors are associated with the diversity of treatments, including patients' characteristics, and prescriptors criteria.</dc:description>
</entry>
<entry>
<title>Quantificação de ácido kójico em estudos de permeação in vitro</title>
<link href="http://sedici.unlp.edu.ar:80/handle/10915/7519" rel="alternate"/>
<author>
<name>Oliveira, Robson V. M.</name>
</author>
<author>
<name>Ohara, Mitsuko T.</name>
</author>
<author>
<name>Gonçalves, Marcos M.</name>
</author>
<author>
<name>Vila, Marta M. D. C.</name>
</author>
<id>http://sedici.unlp.edu.ar:80/handle/10915/7519</id>
<updated>2012-05-03T01:50:20Z</updated>
<published>2007-01-01T00:00:00Z</published>
<summary type="text">Articulo
Quantfication of kojic acid in vitro permeation studies
Latin American Journal of Pharmacy; vol. 26, no. 4
A eficácia de substâncias clareadoras, como o ácido kójico (AK), pode ser avaliada, em relação à capacidade de penetração, através de estudos de permeação, que necessitam de métodos de quantificação específicos. Neste trabalho, desenvolveu-se método espectrofotométrico para a quantificação do AK em solução salina. O comprimento de onda de máxima absorção foi 268 nm e a curva de calibração, apresentouse linear na faixa de 0,05 a 4,00 &amp;#956;g/mL. O limite de detecção e quantificação foram 0,06 e 0,18 &amp;#956;g/mL, respectivamente. A precisão foi de 2,3 a 5,3% intra-dia, 1,6 a 5,4% inter-dia e exatidão de 98 a 101%.; The pigmentation-lowering agents efficacy, like kojic acid (KA), can be evaluated according to its penetration capacity, by permeation studies that need specific quantification methods. In this work, a spectrophotometric method have been developed for KA quantification in saline solution. The wave length of maximum absorbance was 268 nm and calibration curve was linear from 0.05 to 4.00 &amp;#956;/gmL. Detection and quantification limits were 0.06 and 0.18 &amp;#956;g/mL respectively. The precision was 2.3 to 5.3% intraday, 1.6 to 5.4% interday, and the accuracy was 98 to 101%.
</summary>
<dc:date>2007-01-01T00:00:00Z</dc:date>
<dc:description>A eficácia de substâncias clareadoras, como o ácido kójico (AK), pode ser avaliada, em relação à capacidade de penetração, através de estudos de permeação, que necessitam de métodos de quantificação específicos. Neste trabalho, desenvolveu-se método espectrofotométrico para a quantificação do AK em solução salina. O comprimento de onda de máxima absorção foi 268 nm e a curva de calibração, apresentouse linear na faixa de 0,05 a 4,00 &amp;#956;g/mL. O limite de detecção e quantificação foram 0,06 e 0,18 &amp;#956;g/mL, respectivamente. A precisão foi de 2,3 a 5,3% intra-dia, 1,6 a 5,4% inter-dia e exatidão de 98 a 101%.

The pigmentation-lowering agents efficacy, like kojic acid (KA), can be evaluated according to its penetration capacity, by permeation studies that need specific quantification methods. In this work, a spectrophotometric method have been developed for KA quantification in saline solution. The wave length of maximum absorbance was 268 nm and calibration curve was linear from 0.05 to 4.00 &amp;#956;/gmL. Detection and quantification limits were 0.06 and 0.18 &amp;#956;g/mL respectively. The precision was 2.3 to 5.3% intraday, 1.6 to 5.4% interday, and the accuracy was 98 to 101%.</dc:description>
</entry>
<entry>
<title>Estudo de bioequivalência farmacêutica de duas formulações orais de Aciclovir em voluntários sadios</title>
<link href="http://sedici.unlp.edu.ar:80/handle/10915/7518" rel="alternate"/>
<author>
<name>Pugens, Ana M.</name>
</author>
<author>
<name>Vieira, Daiane</name>
</author>
<author>
<name>Santos, Maurício B. dos</name>
</author>
<author>
<name>Pritsch, Mariely C.</name>
</author>
<author>
<name>Manfio, Josélia L.</name>
</author>
<id>http://sedici.unlp.edu.ar:80/handle/10915/7518</id>
<updated>2012-05-03T01:50:20Z</updated>
<published>2007-01-01T00:00:00Z</published>
<summary type="text">Comunicacion
Bioequivalence study of two formulations of Acyclovir in healthy volunteers
Latin American Journal of Pharmacy; vol. 26, no. 4
Este estudo tem com objetivo avaliar a bioequivalência de duas formulações de aciclovir 200 mg comprimido. O estudo foi aberto, randomizado, dois períodos crossover com uma semana de washout. As amostras de sangue foram coletadas por um período de 16 h após a administração do produto referência, Zovirax® e o produto teste, Aciclovir para 32 voluntários em jejum. Um método simples, exato, preciso e sensível, utilizando cromatografia líquida de alta eficiência (CLAE) foi desenvolvido e validado para quantificação de aciclovir em plasma após extração líquido - líquido. A bioequivalência entre os produtos foi determinada através do cálculo de intervalo de confiança (90%) para a razão das médias geométricas, C&lt;sub&gt;max&lt;/sub&gt; , ASC&lt;sub&gt;0&amp;#8211;t&lt;/sub&gt; and ASC&lt;sub&gt;0&amp;#8211;&amp;#8734;&lt;/sub&gt;, dos dados transformados dos produtos teste e referência. O intervalo de confiança 90% para a razão de C&lt;sub&gt;max&lt;/sub&gt; foi 83.86% e 105.83%, ASC&lt;sub&gt;0&amp;#8211;t&lt;/sub&gt; 86.67% e 111.37%, ASC&lt;sub&gt;0&amp;#8211;&amp;#8734;&lt;/sub&gt; 87.76% e 110.87%, estes valores estão dentro do intervalo de 80-125%, proposto pela ANVISA. Conclui-se que as duas formulações são bioequivalente quanto à taxa e extensão de absorção; The purpose of this study was to evaluate bioequivalence of two commercial 200 mg tablet formulations of acyclovir. The study was an open, randomized, two-period crossover trial with a 1-week washout interval. Blood samples were collected throughout a 16-h period after administration of reference product, Zovirax® and test product, Acyclovir to 32 fasting volunteers. A simple, accurate, precise and sensitive high-performance liquid chromatographic (HPLC) method with ultraviolet detection was developed and validated for quantification of acyclovir in plasma samples after liquid-liquid extraction. Bioequivalence between the products was determined by calculating 90% confidence intervals (90% I.C) for the ratio of C&lt;sub&gt;max&lt;/sub&gt; , AUC&lt;sub&gt;0&amp;#8211;t&lt;/sub&gt; and AUC&lt;sub&gt;0&amp;#8211;&amp;#8734;&lt;/sub&gt; values for the test and reference products, using logarithmic transformed data. The 90% confidence intervals for the ratio of C&lt;sub&gt;max&lt;/sub&gt; (83.86-105.83%), AUC&lt;sub&gt;0&amp;#8211;t&lt;/sub&gt; (86.67-111.379%) and (87.76-110.87%) values for the test and reference products are within the 80- 125% interval, proposed by ANVISA. It was concluded that the two acyclovir formulations are bioequivalent in their rate and extent of absorption.
</summary>
<dc:date>2007-01-01T00:00:00Z</dc:date>
<dc:description>Este estudo tem com objetivo avaliar a bioequivalência de duas formulações de aciclovir 200 mg comprimido. O estudo foi aberto, randomizado, dois períodos crossover com uma semana de washout. As amostras de sangue foram coletadas por um período de 16 h após a administração do produto referência, Zovirax® e o produto teste, Aciclovir para 32 voluntários em jejum. Um método simples, exato, preciso e sensível, utilizando cromatografia líquida de alta eficiência (CLAE) foi desenvolvido e validado para quantificação de aciclovir em plasma após extração líquido - líquido. A bioequivalência entre os produtos foi determinada através do cálculo de intervalo de confiança (90%) para a razão das médias geométricas, C&lt;sub&gt;max&lt;/sub&gt; , ASC&lt;sub&gt;0&amp;#8211;t&lt;/sub&gt; and ASC&lt;sub&gt;0&amp;#8211;&amp;#8734;&lt;/sub&gt;, dos dados transformados dos produtos teste e referência. O intervalo de confiança 90% para a razão de C&lt;sub&gt;max&lt;/sub&gt; foi 83.86% e 105.83%, ASC&lt;sub&gt;0&amp;#8211;t&lt;/sub&gt; 86.67% e 111.37%, ASC&lt;sub&gt;0&amp;#8211;&amp;#8734;&lt;/sub&gt; 87.76% e 110.87%, estes valores estão dentro do intervalo de 80-125%, proposto pela ANVISA. Conclui-se que as duas formulações são bioequivalente quanto à taxa e extensão de absorção

The purpose of this study was to evaluate bioequivalence of two commercial 200 mg tablet formulations of acyclovir. The study was an open, randomized, two-period crossover trial with a 1-week washout interval. Blood samples were collected throughout a 16-h period after administration of reference product, Zovirax® and test product, Acyclovir to 32 fasting volunteers. A simple, accurate, precise and sensitive high-performance liquid chromatographic (HPLC) method with ultraviolet detection was developed and validated for quantification of acyclovir in plasma samples after liquid-liquid extraction. Bioequivalence between the products was determined by calculating 90% confidence intervals (90% I.C) for the ratio of C&lt;sub&gt;max&lt;/sub&gt; , AUC&lt;sub&gt;0&amp;#8211;t&lt;/sub&gt; and AUC&lt;sub&gt;0&amp;#8211;&amp;#8734;&lt;/sub&gt; values for the test and reference products, using logarithmic transformed data. The 90% confidence intervals for the ratio of C&lt;sub&gt;max&lt;/sub&gt; (83.86-105.83%), AUC&lt;sub&gt;0&amp;#8211;t&lt;/sub&gt; (86.67-111.379%) and (87.76-110.87%) values for the test and reference products are within the 80- 125% interval, proposed by ANVISA. It was concluded that the two acyclovir formulations are bioequivalent in their rate and extent of absorption.</dc:description>
</entry>
<entry>
<title>Determinación del factor de protección solar de dos protectores solares elaborados en un recetario magistral</title>
<link href="http://sedici.unlp.edu.ar:80/handle/10915/7517" rel="alternate"/>
<author>
<name>Costa, Edda</name>
</author>
<author>
<name>Villegas, Carlos</name>
</author>
<author>
<name>Donoso, Lucrecia</name>
</author>
<author>
<name>Correa, Olosmira</name>
</author>
<id>http://sedici.unlp.edu.ar:80/handle/10915/7517</id>
<updated>2012-05-03T01:50:20Z</updated>
<published>2007-01-01T00:00:00Z</published>
<summary type="text">Comunicacion
Evaluation of the sun protection factor of two sunscreens made up in a pharmacy
Latin American Journal of Pharmacy; vol. 26, no. 4
El propósito de este estudio fue evaluar el Factor de Protección Solar de dos protectores solares&#13;
elaborados en un Recetario Magistral utilizando una adaptación de la técnica recomendada por la Food&#13;
and Drug Administration (FDA). En el estudio participaron 20 voluntarios, a los cuales se les determinó&#13;
previamente la Dosis Eritematosa Mínima (DEM) con y sin protector, y posteriormente el Factor de&#13;
Protección Solar (FPS) de los protectores solares. La DEM promedio de los voluntarios en piel sin protección,&#13;
con protector solar I y II fue de 9,7 mJ/cm2; 252,6 mJ/cm2 y 429,1 mJ/cm2, respectivamente. Los valores&#13;
de FPS promedio y desviación estándar obtenidos con los protectores solares en cada voluntario, fueron&#13;
de: 26,6 ± 2,53 para el producto I y de 44,7 ± 3,06 para el producto II. Los valores de FPS calculados&#13;
para el protector solar I y II fueron de 26,6 y de 44,7 respectivamente, valores inferiores a los señalados&#13;
por el fabricante.; The purpose&#13;
of this study was to evaluate in vivo the Sun Protection Factor (SPF) of two sunscreens made in a pharmacy, utilizing&#13;
for such purpose a technique described by the Food and Drug Administration (FDA). This study was carried&#13;
out with 20 subjects that voluntarily accepted to participate. The evaluation consisted to determine the minimal&#13;
erythema dose (MED) of the volunteers with and without protector. The MED average of the volunteers was&#13;
9.7 mJ/cm2 without protection; 252.6 mJ/cm2 for sunscreen I and 429.1 mJ/cm2 for sunscreen II. The values of&#13;
SPF average and standard deviation were 26.6 ± 2.53 for sunscreen I and 44.7 ± 3.06 for sunscreen II. The values&#13;
calculated for sunscreens I and II were 26.6 and 44.7, respectively. These values were smaller than those specified&#13;
by the manufacturer.
</summary>
<dc:date>2007-01-01T00:00:00Z</dc:date>
<dc:description>El propósito de este estudio fue evaluar el Factor de Protección Solar de dos protectores solares&#13;
elaborados en un Recetario Magistral utilizando una adaptación de la técnica recomendada por la Food&#13;
and Drug Administration (FDA). En el estudio participaron 20 voluntarios, a los cuales se les determinó&#13;
previamente la Dosis Eritematosa Mínima (DEM) con y sin protector, y posteriormente el Factor de&#13;
Protección Solar (FPS) de los protectores solares. La DEM promedio de los voluntarios en piel sin protección,&#13;
con protector solar I y II fue de 9,7 mJ/cm2; 252,6 mJ/cm2 y 429,1 mJ/cm2, respectivamente. Los valores&#13;
de FPS promedio y desviación estándar obtenidos con los protectores solares en cada voluntario, fueron&#13;
de: 26,6 ± 2,53 para el producto I y de 44,7 ± 3,06 para el producto II. Los valores de FPS calculados&#13;
para el protector solar I y II fueron de 26,6 y de 44,7 respectivamente, valores inferiores a los señalados&#13;
por el fabricante.

The purpose&#13;
of this study was to evaluate in vivo the Sun Protection Factor (SPF) of two sunscreens made in a pharmacy, utilizing&#13;
for such purpose a technique described by the Food and Drug Administration (FDA). This study was carried&#13;
out with 20 subjects that voluntarily accepted to participate. The evaluation consisted to determine the minimal&#13;
erythema dose (MED) of the volunteers with and without protector. The MED average of the volunteers was&#13;
9.7 mJ/cm2 without protection; 252.6 mJ/cm2 for sunscreen I and 429.1 mJ/cm2 for sunscreen II. The values of&#13;
SPF average and standard deviation were 26.6 ± 2.53 for sunscreen I and 44.7 ± 3.06 for sunscreen II. The values&#13;
calculated for sunscreens I and II were 26.6 and 44.7, respectively. These values were smaller than those specified&#13;
by the manufacturer.</dc:description>
</entry>
<entry>
<title>Actividad antimicrobiana in vitro de seis especies autóctonas de la flora de Entre Ríos (Argentina)</title>
<link href="http://sedici.unlp.edu.ar:80/handle/10915/7516" rel="alternate"/>
<author>
<name>Vivot, Eduardo</name>
</author>
<author>
<name>Massa, Roxana</name>
</author>
<author>
<name>Cruañes, María J.</name>
</author>
<author>
<name>Muñoz, Juan de Dios</name>
</author>
<author>
<name>Ferraro, Graciela Ester</name>
</author>
<author>
<name>Gutkind, Gabriel Osvaldo</name>
</author>
<author>
<name>Martino, Virginia S.</name>
</author>
<id>http://sedici.unlp.edu.ar:80/handle/10915/7516</id>
<updated>2012-05-03T01:50:20Z</updated>
<published>2007-01-01T00:00:00Z</published>
<summary type="text">Comunicacion
In vitro antimicrobial activity of six native species from Entre Rios flora (Argentina)
Latin American Journal of Pharmacy; vol. 26, no. 4
Los extractos de cinco plantas de la flora de Entre Ríos (Argentina), usadas como antisépticos&#13;
en medicina popular, fueron ensayados frente a bacterias y hongos para la evaluación de sus actividades&#13;
antimicrobianas mediante el método de difusión con discos. El extracto diclorometánico de Acanthospermum&#13;
australe y de Polygonum punctatum y el extracto hidroalcohólico de Arctium minus fue activo contra&#13;
Bacillus subtillis, Micrococcus luteus, Listeria monocytogenes y Staphylococcus aureus. El extracto diclorometánico&#13;
de Tessaria integrifolia fue activo contra B. subtilis y S. aureus. El extracto metanólico de P.&#13;
punctatum fue activo contra B. subtilis, M. luteus. L. monocytogenes y S. aureus. El extracto hidroalcohólico&#13;
de A. australe evidenció actividad contra B. subtilis, M. luteus y S. aureus. El extracto metanólico de P.&#13;
punctatum resultó activo contra Aspergillus níger y el extracto diclorometánico de P. punctatum contra&#13;
Candida albicans y A. niger. Entre las especies de plantas ensayadas, los extractos de P. punctatum fueron&#13;
los que presentaron el mayor espectro de actividad.; Extracts&#13;
of five plants from Entre Ríos flora (Argentina) traditionally used in folk medicine as antiseptics for external use&#13;
and/or in the treatment of diseases that could be related to microbial infections were selected for the evaluation of&#13;
their antimicrobial activities using a disk diffusion test. Dichloromethane, methanolic, hydroalcoholic and aqueous&#13;
extracts of all species were tested against a representative set of bacteria and fungi. Results showed the activity&#13;
of the dichloromethane extracts of Acanthospermum australe and Polygonum punctatum and the hydroalcoholic&#13;
extract of Arctium minus against Bacillus subtilis, Micrococcus luteus, Listeria monocytogenes and Staphylococcus&#13;
aureus. The dichloromethane extract of Tessaria integrifolia was active against B.subtilis and S.aureus.&#13;
The methanolic extract of P.punctatum was active against B.subtilis, M. luteus, L. monocytogenes and S.aureus.&#13;
The hydroalcoholic extract of A. australe was active against B. subtilis, M. luteus and S. aureus. Antifungal evaluation&#13;
showed that the methanolic extract of P. punctatum was active against Aspergillus niger and the&#13;
dichloromethanic extract of P. punctatum was active against Candida albicans and A. niger. Within the tested&#13;
plants, P. punctatum extracts displayed the broadest spectrum of activity.
</summary>
<dc:date>2007-01-01T00:00:00Z</dc:date>
<dc:description>Los extractos de cinco plantas de la flora de Entre Ríos (Argentina), usadas como antisépticos&#13;
en medicina popular, fueron ensayados frente a bacterias y hongos para la evaluación de sus actividades&#13;
antimicrobianas mediante el método de difusión con discos. El extracto diclorometánico de Acanthospermum&#13;
australe y de Polygonum punctatum y el extracto hidroalcohólico de Arctium minus fue activo contra&#13;
Bacillus subtillis, Micrococcus luteus, Listeria monocytogenes y Staphylococcus aureus. El extracto diclorometánico&#13;
de Tessaria integrifolia fue activo contra B. subtilis y S. aureus. El extracto metanólico de P.&#13;
punctatum fue activo contra B. subtilis, M. luteus. L. monocytogenes y S. aureus. El extracto hidroalcohólico&#13;
de A. australe evidenció actividad contra B. subtilis, M. luteus y S. aureus. El extracto metanólico de P.&#13;
punctatum resultó activo contra Aspergillus níger y el extracto diclorometánico de P. punctatum contra&#13;
Candida albicans y A. niger. Entre las especies de plantas ensayadas, los extractos de P. punctatum fueron&#13;
los que presentaron el mayor espectro de actividad.

Extracts&#13;
of five plants from Entre Ríos flora (Argentina) traditionally used in folk medicine as antiseptics for external use&#13;
and/or in the treatment of diseases that could be related to microbial infections were selected for the evaluation of&#13;
their antimicrobial activities using a disk diffusion test. Dichloromethane, methanolic, hydroalcoholic and aqueous&#13;
extracts of all species were tested against a representative set of bacteria and fungi. Results showed the activity&#13;
of the dichloromethane extracts of Acanthospermum australe and Polygonum punctatum and the hydroalcoholic&#13;
extract of Arctium minus against Bacillus subtilis, Micrococcus luteus, Listeria monocytogenes and Staphylococcus&#13;
aureus. The dichloromethane extract of Tessaria integrifolia was active against B.subtilis and S.aureus.&#13;
The methanolic extract of P.punctatum was active against B.subtilis, M. luteus, L. monocytogenes and S.aureus.&#13;
The hydroalcoholic extract of A. australe was active against B. subtilis, M. luteus and S. aureus. Antifungal evaluation&#13;
showed that the methanolic extract of P. punctatum was active against Aspergillus niger and the&#13;
dichloromethanic extract of P. punctatum was active against Candida albicans and A. niger. Within the tested&#13;
plants, P. punctatum extracts displayed the broadest spectrum of activity.</dc:description>
</entry>
<entry>
<title>Avaliação da estabilidade físico-química de creme não iônico inscrito no formulário nacional</title>
<link href="http://sedici.unlp.edu.ar:80/handle/10915/7515" rel="alternate"/>
<author>
<name>Friedrich, Milene</name>
</author>
<author>
<name>Teixeira Primo, Fabián</name>
</author>
<author>
<name>Funck, Jose Aparicio Brittes</name>
</author>
<author>
<name>Varini Laporta, Luciane</name>
</author>
<author>
<name>Palma Alves, Marta</name>
</author>
<author>
<name>Figueiredo Bittencourt, Celso</name>
</author>
<author>
<name>Venquiarutti Escarrone, Ana Laura</name>
</author>
<id>http://sedici.unlp.edu.ar:80/handle/10915/7515</id>
<updated>2012-05-03T01:50:20Z</updated>
<published>2007-01-01T00:00:00Z</published>
<summary type="text">Comunicacion
Physico-chemical stability evaluation of a non-ionic cream (base) included on national formulary
Latin American Journal of Pharmacy; vol. 26, no. 4
O Formulário Nacional (FN) é o código oficial brasileiro onde estão inscritas formulações farmacêuticas&#13;
oficiais, e tem como objetivo a padronização dos medicamentos e cosméticos nele inscritos, com&#13;
o intuito de assegurar a qualidade dos mesmos. Entre as bases de uso dermatológico constante na referida&#13;
obra, o creme não iônico destaca-se pela facilidade em incorporar princípios ativos farmacêuticos e cosméticos,&#13;
sendo amplamente utilizado como veículo, em diversas formulações. Partindo-se do pressuposto de&#13;
que as formulações inscritas no FN devem ter estabilidade assegurada, o presente trabalho teve como objetivo&#13;
avaliar a estabilidade e as características físico-químicas desta base. Este estudo foi iniciado com o&#13;
preparo do creme seguindo metodologia preconizada no FN. As amostras foram analisadas com respeito&#13;
às propriedades organolépticas, variação de pH, viscosidade, espalhabilidade e distribuição do tamanho de&#13;
partículas, durante 12 semanas. Foi observado neste experimento que o produto apresentou comportamento&#13;
pseudoplástico. Apesar de a viscosidade ter sido alterada comparando-se os valores iniciais e finais&#13;
e, estas alterações provocaram mudanças significativas nos valores de espalhabilidade, a mesma continuou&#13;
apresentando boa estabilidade, caracterizando-se como um veículo apropriado para incorporação de fármacos.; The National Formulary (NF) is the Brazilian official code where are contained official pharmaceutical&#13;
formulations in order to standardize related drugs and cosmetics, assuring their quality. Among the indexed dermatological&#13;
bases, non-ionic cream stands out because of its ease to incorpore pharmaceutical and cosmetic active&#13;
principles, widely being used as vehicle in several formulations. Considering that listed formulations must&#13;
have guaranteed stability, the present study purposed to assess stability and physico-chemical characteristics of&#13;
this base. This study started with the cream preparation according to NF methodology. Samples were evaluated&#13;
about organoleptic properties, pH variation, viscosity, spreadability and distribution of particle sizes during&#13;
twelve weeks. In this study, it was noticed that the product showed a good pseudoplastic behavior. Except for the&#13;
viscosity that was altered compared to starting and ending values and it brought about significative changes on&#13;
spreadability values, the base showed good stability and seemed to be an appropriate vehicle for drug incorporations.
</summary>
<dc:date>2007-01-01T00:00:00Z</dc:date>
<dc:description>O Formulário Nacional (FN) é o código oficial brasileiro onde estão inscritas formulações farmacêuticas&#13;
oficiais, e tem como objetivo a padronização dos medicamentos e cosméticos nele inscritos, com&#13;
o intuito de assegurar a qualidade dos mesmos. Entre as bases de uso dermatológico constante na referida&#13;
obra, o creme não iônico destaca-se pela facilidade em incorporar princípios ativos farmacêuticos e cosméticos,&#13;
sendo amplamente utilizado como veículo, em diversas formulações. Partindo-se do pressuposto de&#13;
que as formulações inscritas no FN devem ter estabilidade assegurada, o presente trabalho teve como objetivo&#13;
avaliar a estabilidade e as características físico-químicas desta base. Este estudo foi iniciado com o&#13;
preparo do creme seguindo metodologia preconizada no FN. As amostras foram analisadas com respeito&#13;
às propriedades organolépticas, variação de pH, viscosidade, espalhabilidade e distribuição do tamanho de&#13;
partículas, durante 12 semanas. Foi observado neste experimento que o produto apresentou comportamento&#13;
pseudoplástico. Apesar de a viscosidade ter sido alterada comparando-se os valores iniciais e finais&#13;
e, estas alterações provocaram mudanças significativas nos valores de espalhabilidade, a mesma continuou&#13;
apresentando boa estabilidade, caracterizando-se como um veículo apropriado para incorporação de fármacos.

The National Formulary (NF) is the Brazilian official code where are contained official pharmaceutical&#13;
formulations in order to standardize related drugs and cosmetics, assuring their quality. Among the indexed dermatological&#13;
bases, non-ionic cream stands out because of its ease to incorpore pharmaceutical and cosmetic active&#13;
principles, widely being used as vehicle in several formulations. Considering that listed formulations must&#13;
have guaranteed stability, the present study purposed to assess stability and physico-chemical characteristics of&#13;
this base. This study started with the cream preparation according to NF methodology. Samples were evaluated&#13;
about organoleptic properties, pH variation, viscosity, spreadability and distribution of particle sizes during&#13;
twelve weeks. In this study, it was noticed that the product showed a good pseudoplastic behavior. Except for the&#13;
viscosity that was altered compared to starting and ending values and it brought about significative changes on&#13;
spreadability values, the base showed good stability and seemed to be an appropriate vehicle for drug incorporations.</dc:description>
</entry>
<entry>
<title>Tecnología de la formulación farmacéutica de un probiótico (Zimomonas mobilis) en cápsulas de gelatina duras</title>
<link href="http://sedici.unlp.edu.ar:80/handle/10915/7514" rel="alternate"/>
<author>
<name>Jales, Silvana T. L.</name>
</author>
<author>
<name>Soares Sobrinho, José L.</name>
</author>
<author>
<name>Nunes, Lívio C. C.</name>
</author>
<author>
<name>Roca, Mónica F.</name>
</author>
<author>
<name>Lima, Ednaldo Queiroga de</name>
</author>
<author>
<name>Ximenes, Eulalia A.</name>
</author>
<author>
<name>Rolim Neto, Pedró José</name>
</author>
<id>http://sedici.unlp.edu.ar:80/handle/10915/7514</id>
<updated>2012-05-03T01:50:20Z</updated>
<published>2007-01-01T00:00:00Z</published>
<summary type="text">Articulo
Formulation technology of a probiotic (Zymomonas mobilis) in gelatinous capsules
Latin American Journal of Pharmacy; vol. 26, no. 4
Este estudio tuvo como objetivo la obtención de un probiótico en la forma farmacéutica cápsula utilizando como materia prima Zimomonas mobilis fermentado. La liofilización del fermentado de Z. mobilis en una solución crioprotectora (10% de sacarosa, 1% de gelatina y 4% de dióxido de silicio coloidal) resultó ser la mejor formulación alcanzada. Las cápsulas obtenidas a partir de este producto liofilizado presentaron uniformidad de masa, tiempo de disgregación y disolución satisfactorios, además de un bajo porcentaje de humedad en el lote a escala de laboratorio, al igual que para el lote a escala semi-industrial. El proceso tecnológico utilizado no alteró la viabilidad de las células de Z. mobilis.; This study aimed the obtainment of a probiotic in the pharmaceutical form of capsules by using fermented Zymomonas mobilis standardized as raw matter. Lyophilization of the fermented Z. mobilis with a cryoprotective solution (10% saccharose, 1% gelatin and 4% colloidal silicon dioxide) resulted on the best formulation obtained. The capsules obtained from that product of lyophilization had uniform weight, satisfactory time of desintegration and dissolution, and low humidity content, both in the laboratory&#13;
scale and in the transposition to the semi-industrial scale. The technological processes used did not alter Z. mobilis cell viability.
</summary>
<dc:date>2007-01-01T00:00:00Z</dc:date>
<dc:description>Este estudio tuvo como objetivo la obtención de un probiótico en la forma farmacéutica cápsula utilizando como materia prima Zimomonas mobilis fermentado. La liofilización del fermentado de Z. mobilis en una solución crioprotectora (10% de sacarosa, 1% de gelatina y 4% de dióxido de silicio coloidal) resultó ser la mejor formulación alcanzada. Las cápsulas obtenidas a partir de este producto liofilizado presentaron uniformidad de masa, tiempo de disgregación y disolución satisfactorios, además de un bajo porcentaje de humedad en el lote a escala de laboratorio, al igual que para el lote a escala semi-industrial. El proceso tecnológico utilizado no alteró la viabilidad de las células de Z. mobilis.

This study aimed the obtainment of a probiotic in the pharmaceutical form of capsules by using fermented Zymomonas mobilis standardized as raw matter. Lyophilization of the fermented Z. mobilis with a cryoprotective solution (10% saccharose, 1% gelatin and 4% colloidal silicon dioxide) resulted on the best formulation obtained. The capsules obtained from that product of lyophilization had uniform weight, satisfactory time of desintegration and dissolution, and low humidity content, both in the laboratory&#13;
scale and in the transposition to the semi-industrial scale. The technological processes used did not alter Z. mobilis cell viability.</dc:description>
</entry>
<entry>
<title>Efecto antiinflamatorio preclínico del polvo seco de Caléndula officinalis</title>
<link href="http://sedici.unlp.edu.ar:80/handle/10915/7513" rel="alternate"/>
<author>
<name>Núñez Figueredo, Yanier</name>
</author>
<author>
<name>Montero Alarcón, Claudia</name>
</author>
<author>
<name>Agüero Fernández, Sara</name>
</author>
<author>
<name>Muñoz Cernuda, Adriana</name>
</author>
<id>http://sedici.unlp.edu.ar:80/handle/10915/7513</id>
<updated>2012-05-03T01:50:20Z</updated>
<published>2007-01-01T00:00:00Z</published>
<summary type="text">Articulo
Preclinical anti-inflammatory effects of dry powder of Caléndula officinalis
Latin American Journal of Pharmacy; vol. 26, no. 4
Para demostrar la actividad antiinflamatoria del polvo seco Caléndula officinalis secado por atomización se emplearon dosis de 50, 150 y 450 mg/Kg y se evaluó el efecto sobre la inflamación aguda provocada por carragenina, dextrán, histamina y serotonina y granuloma inducido por discos de algodón en ratas y edema auricular inducido por aceite de crotón en ratones. El polvo seco mostró efecto inhibitorio sobre los diferentes modelos empleados sin afectar el peso del timo y las glándulas suprarrenales. Estos resultados muestran que el método de secado por atomización permite la obtención de una materia prima de Caléndula officinalis activa frente a procesos inflamatorios de naturaleza diversa.; With the objective to demonstrate the anti-inflammatory effect of Calendula officinalis dry powder, doses of 50, 150 and 450 were used on inflammation induced by carragenin, dextran, histamine and serotonine, the granulome induced by cotton pellets in rats and ear inflammation induced by croton oil in mice. The spray dried powder of Calendula officinalis inhibited the inflammatory process in all animal model employed without affecting tymus's and adrenal's weight. These results show that the powder of Calendula officinalis obtained by spray drying is active in inflammatory processes of diverse nature.
</summary>
<dc:date>2007-01-01T00:00:00Z</dc:date>
<dc:description>Para demostrar la actividad antiinflamatoria del polvo seco Caléndula officinalis secado por atomización se emplearon dosis de 50, 150 y 450 mg/Kg y se evaluó el efecto sobre la inflamación aguda provocada por carragenina, dextrán, histamina y serotonina y granuloma inducido por discos de algodón en ratas y edema auricular inducido por aceite de crotón en ratones. El polvo seco mostró efecto inhibitorio sobre los diferentes modelos empleados sin afectar el peso del timo y las glándulas suprarrenales. Estos resultados muestran que el método de secado por atomización permite la obtención de una materia prima de Caléndula officinalis activa frente a procesos inflamatorios de naturaleza diversa.

With the objective to demonstrate the anti-inflammatory effect of Calendula officinalis dry powder, doses of 50, 150 and 450 were used on inflammation induced by carragenin, dextran, histamine and serotonine, the granulome induced by cotton pellets in rats and ear inflammation induced by croton oil in mice. The spray dried powder of Calendula officinalis inhibited the inflammatory process in all animal model employed without affecting tymus's and adrenal's weight. These results show that the powder of Calendula officinalis obtained by spray drying is active in inflammatory processes of diverse nature.</dc:description>
</entry>
<entry>
<title>Influência do Kollidon® 90F e do Polyox® WSR301NF na força de adesão de comprimidos bucais de Clorexidina</title>
<link href="http://sedici.unlp.edu.ar:80/handle/10915/7512" rel="alternate"/>
<author>
<name>Ferrarini, Márcio</name>
</author>
<author>
<name>Rolim Baby, André</name>
</author>
<author>
<name>Pinto, Claudinéia A. S. O.</name>
</author>
<author>
<name>Velasco, María Valéria R.</name>
</author>
<author>
<name>Pinto, Terezinha J. A.</name>
</author>
<author>
<name>Kaneko, Telma Mary</name>
</author>
<id>http://sedici.unlp.edu.ar:80/handle/10915/7512</id>
<updated>2012-05-03T01:50:21Z</updated>
<published>2007-01-01T00:00:00Z</published>
<summary type="text">Articulo
Inlfuence of Kollidon® 90F and Polyox® WSR301NF on the adhesion strength of chlorexidine bucoadhesive tablets
Latin American Journal of Pharmacy; vol. 26, no. 4
Com o intuito de buscar uma nova alternativa para o tratamento das infecções do ambiente&#13;
bucal, o trabalho propôs a utilização de comprimidos bucais adesivos contendo acetato de clorexidina. Foram&#13;
desenvolvidas 17 formulações contendo 5 mg do fármaco e com peso teórico de 150 mg. Os comprimidos&#13;
continham diferentes relações de concentração entre lactose, Kollidon® 90 F (povidona USP) e&#13;
Poliox® WSR 301 NF (polietilenoglicol NF), segundo o planejamento estatístico de mistura "simplex". As&#13;
preparações foram avaliadas quanto à sua dureza, peso médio, dimensões e adesividade. Os excipientes&#13;
Kollidon® e Poliox® produziram comprimidos com características adesivas satisfatórias, sendo que aqueles&#13;
com maior teor de Kollidon® forneceram valores de adesão ligeiramente mais elevados.; Searching for a new alternative for the treatement of oral infections, this work proposed&#13;
the utilization of chlorexidine acetate adhesive tablets. Seventeen formulations with 5 mg of the active ingredient&#13;
and theoretical weight of 150 mg were developed. The tablets were developed with lactose, Kollidon® 90 F&#13;
(povidone USP) and Poliox® WSR 301 NF (polietileneglicol NF) in different concentration ratios, based on the&#13;
statistical ¨simplex¨ mixture aproach. The hardness, average weight, dimentions and adhesive force were evaluated.&#13;
Kollidon® and Poliox® produced tablets with good adhesives values, with higher values for Kollidon®.
</summary>
<dc:date>2007-01-01T00:00:00Z</dc:date>
<dc:description>Com o intuito de buscar uma nova alternativa para o tratamento das infecções do ambiente&#13;
bucal, o trabalho propôs a utilização de comprimidos bucais adesivos contendo acetato de clorexidina. Foram&#13;
desenvolvidas 17 formulações contendo 5 mg do fármaco e com peso teórico de 150 mg. Os comprimidos&#13;
continham diferentes relações de concentração entre lactose, Kollidon® 90 F (povidona USP) e&#13;
Poliox® WSR 301 NF (polietilenoglicol NF), segundo o planejamento estatístico de mistura "simplex". As&#13;
preparações foram avaliadas quanto à sua dureza, peso médio, dimensões e adesividade. Os excipientes&#13;
Kollidon® e Poliox® produziram comprimidos com características adesivas satisfatórias, sendo que aqueles&#13;
com maior teor de Kollidon® forneceram valores de adesão ligeiramente mais elevados.

Searching for a new alternative for the treatement of oral infections, this work proposed&#13;
the utilization of chlorexidine acetate adhesive tablets. Seventeen formulations with 5 mg of the active ingredient&#13;
and theoretical weight of 150 mg were developed. The tablets were developed with lactose, Kollidon® 90 F&#13;
(povidone USP) and Poliox® WSR 301 NF (polietileneglicol NF) in different concentration ratios, based on the&#13;
statistical ¨simplex¨ mixture aproach. The hardness, average weight, dimentions and adhesive force were evaluated.&#13;
Kollidon® and Poliox® produced tablets with good adhesives values, with higher values for Kollidon®.</dc:description>
</entry>
<entry>
<title>Efectos de la terapia combinada del D-004 y el Finasteride sobre la hiperplasia de próstata inducida por testosterona en ratas</title>
<link href="http://sedici.unlp.edu.ar:80/handle/10915/7511" rel="alternate"/>
<author>
<name>Molina, Vivian</name>
</author>
<author>
<name>Arruzazabala, María de Lourdes</name>
</author>
<author>
<name>Carvajal, Daysi</name>
</author>
<author>
<name>Más, Rosa</name>
</author>
<id>http://sedici.unlp.edu.ar:80/handle/10915/7511</id>
<updated>2012-05-03T01:50:21Z</updated>
<published>2007-01-01T00:00:00Z</published>
<summary type="text">Articulo
Effects of D-004 plus Finasteride on prostate hyperplasia induced with testosterone in rats
Latin American Journal of Pharmacy; vol. 26, no. 4
La hiperplasia prostática benigna (HPB) es la causa principal de los síntomas molestos del tracto bajo urinario en el hombre adulto. El finasteride, un inhibidor de la enzima 5&amp;#945;-reductasa prostática es un agente terapéutico ampliamente utilizado en la HPB. El D-004, un extracto lipídico obtenido del fruto de Roystonea regia, previene la hiperplasia de próstata inducida con testosterona (T) pero no con dihidrotestosterona (DHT) en roedores. Este estudio fue realizado con el objetivo de evaluar si la terapia combinada con D-004 + finasteride puede inducir beneficios adicionales sobre la hiperplasia de próstata inducida por T en ratas comparada con las respectivas monoterapias. Primeramente, se ensayó la relación dosis-efecto del finasteride en este modelo, para lo cual las ratas fueron distribuidas en seis grupos (10 ratas/grupo). Un grupo control negativo inyectado con aceite de soya s.c, y cinco grupos inyectados con T (3 mg/kg, s.c): un grupo control positivo tratado solo con el vehículo y cuatro grupos tratados con finasteride (0.5, 1, 3, and 10 mg/kg). Seguidamente, se investigó la posible interacción entre el D-004 y el finasteride, para lo cual las ratas fueron aleatoriamente distribuidas en cinco grupos (10 ratas/grupo): un grupo control negativo, tratado con el vehículo, y cuatro tratados con T: un control positivo y tres grupos tratados con finasteride (0,5 mg/kg), D-004 (200 mg/kg) y terapia combinada de D-004 200 mg/kg + finasteride 0,5 mg/kg, respectivamente. Todos los tratamientos fueron administrados durante 14 días. Se controló el peso corporal semanalmente. Al finalizar el período de tratamiento, las próstatas fueron pesadas. El tratamiento con finasteride (0,5-10 mg/kg) inhibió de modo significativo y dependiente de la dosis el incremento del tamaño de la próstata, en un rango de 45,8% hasta 100%. La terapia combinada inhibió el crecimiento de la próstata en un 63,7%, siendo significativa con relación al control positivo y a cada monoterapia, las cuales inhibieron el incremento del peso de las próstatas en un 32,9% (D-004 200 mg/kg) y 30.6% (finasteride 0,5 mg/kg). En conclusión, la terapia combinada con dosis efectivas mínimas de D-004 y finasteride en este modelo indujo beneficios adicionales en prevenir el alargamiento de la próstata inducido por T comparado con cada tratamiento administrado de forma separada.; Benign prostatic hyperplasia (BPH) is the main cause of lower urinary tract symptoms in older men. Finasteride, a prostate 5&amp;#945;-reductase inhibitor, is a therapeutic agent widely used for BPH. D- 004, a lipid extract from Roystonea regia fruits, prevents prostate hyperplasia (PH) induced with testosterone (T), not with dyhidrotestosterone (DHT) in rodents. This study was undertaken to evaluate whether the combined therapy with D-004 + finasteride could induce additional benefits on T-induce PH in rats compared with the respective monotherapies. Firstly, we assessed the dose-effect relation of finasteride on this model, for which rats were randomly distributed in six groups (10 rats/group). A negative control group injected with soy oil s.c, and five groups injected with T (3 mg/kg, s.c): a positive control treated only with the vehicle and four groups treated with finasteride (0.5, 1, 3, and 10 mg/kg). Later on, the putative interaction between D-004 and finasteride was investigated, for which rats were randomly allocated in five groups (10 rats/group): a negative control, treated with the vehicle, and four treated with T: a positive control and three groups treated with finasteride (0.5 mg/kg), D-004 (200 mg/kg) and combined therapy D-004 200 mg/kg + finasteride 0.5 mg/kg, respectively. All treatments were administered for 14 days. Bodyweight was controlled weekly. At study completion, prostates were weighed. Finasteride (0.5 - 10 mg/kg) significantly and doses dependently inhibited prostate increase, inhibitions ranging from 45.8% to 100%. Combined therapy inhibited prostate enlargement in 63.7%, the reduction on prostate weight being significant versus the positive control and each monotherapy, which at the doses tested inhibited prostate weight increase by 32.9% (D-004 200 mg/kg) and 30.6% (finasteride 0.5 mg/kg). In conclusion, combined therapy with minimal effective doses of both D-004 and finasteride in this model induced additional benefits in preventing T-induced prostate enlargement compared with each treatment administered alone.
</summary>
<dc:date>2007-01-01T00:00:00Z</dc:date>
<dc:description>La hiperplasia prostática benigna (HPB) es la causa principal de los síntomas molestos del tracto bajo urinario en el hombre adulto. El finasteride, un inhibidor de la enzima 5&amp;#945;-reductasa prostática es un agente terapéutico ampliamente utilizado en la HPB. El D-004, un extracto lipídico obtenido del fruto de Roystonea regia, previene la hiperplasia de próstata inducida con testosterona (T) pero no con dihidrotestosterona (DHT) en roedores. Este estudio fue realizado con el objetivo de evaluar si la terapia combinada con D-004 + finasteride puede inducir beneficios adicionales sobre la hiperplasia de próstata inducida por T en ratas comparada con las respectivas monoterapias. Primeramente, se ensayó la relación dosis-efecto del finasteride en este modelo, para lo cual las ratas fueron distribuidas en seis grupos (10 ratas/grupo). Un grupo control negativo inyectado con aceite de soya s.c, y cinco grupos inyectados con T (3 mg/kg, s.c): un grupo control positivo tratado solo con el vehículo y cuatro grupos tratados con finasteride (0.5, 1, 3, and 10 mg/kg). Seguidamente, se investigó la posible interacción entre el D-004 y el finasteride, para lo cual las ratas fueron aleatoriamente distribuidas en cinco grupos (10 ratas/grupo): un grupo control negativo, tratado con el vehículo, y cuatro tratados con T: un control positivo y tres grupos tratados con finasteride (0,5 mg/kg), D-004 (200 mg/kg) y terapia combinada de D-004 200 mg/kg + finasteride 0,5 mg/kg, respectivamente. Todos los tratamientos fueron administrados durante 14 días. Se controló el peso corporal semanalmente. Al finalizar el período de tratamiento, las próstatas fueron pesadas. El tratamiento con finasteride (0,5-10 mg/kg) inhibió de modo significativo y dependiente de la dosis el incremento del tamaño de la próstata, en un rango de 45,8% hasta 100%. La terapia combinada inhibió el crecimiento de la próstata en un 63,7%, siendo significativa con relación al control positivo y a cada monoterapia, las cuales inhibieron el incremento del peso de las próstatas en un 32,9% (D-004 200 mg/kg) y 30.6% (finasteride 0,5 mg/kg). En conclusión, la terapia combinada con dosis efectivas mínimas de D-004 y finasteride en este modelo indujo beneficios adicionales en prevenir el alargamiento de la próstata inducido por T comparado con cada tratamiento administrado de forma separada.

Benign prostatic hyperplasia (BPH) is the main cause of lower urinary tract symptoms in older men. Finasteride, a prostate 5&amp;#945;-reductase inhibitor, is a therapeutic agent widely used for BPH. D- 004, a lipid extract from Roystonea regia fruits, prevents prostate hyperplasia (PH) induced with testosterone (T), not with dyhidrotestosterone (DHT) in rodents. This study was undertaken to evaluate whether the combined therapy with D-004 + finasteride could induce additional benefits on T-induce PH in rats compared with the respective monotherapies. Firstly, we assessed the dose-effect relation of finasteride on this model, for which rats were randomly distributed in six groups (10 rats/group). A negative control group injected with soy oil s.c, and five groups injected with T (3 mg/kg, s.c): a positive control treated only with the vehicle and four groups treated with finasteride (0.5, 1, 3, and 10 mg/kg). Later on, the putative interaction between D-004 and finasteride was investigated, for which rats were randomly allocated in five groups (10 rats/group): a negative control, treated with the vehicle, and four treated with T: a positive control and three groups treated with finasteride (0.5 mg/kg), D-004 (200 mg/kg) and combined therapy D-004 200 mg/kg + finasteride 0.5 mg/kg, respectively. All treatments were administered for 14 days. Bodyweight was controlled weekly. At study completion, prostates were weighed. Finasteride (0.5 - 10 mg/kg) significantly and doses dependently inhibited prostate increase, inhibitions ranging from 45.8% to 100%. Combined therapy inhibited prostate enlargement in 63.7%, the reduction on prostate weight being significant versus the positive control and each monotherapy, which at the doses tested inhibited prostate weight increase by 32.9% (D-004 200 mg/kg) and 30.6% (finasteride 0.5 mg/kg). In conclusion, combined therapy with minimal effective doses of both D-004 and finasteride in this model induced additional benefits in preventing T-induced prostate enlargement compared with each treatment administered alone.</dc:description>
</entry>
<entry>
<title>Equivalencia farmacéutica de comprimidos conteniendo Naproxeno 500 mg</title>
<link href="http://sedici.unlp.edu.ar:80/handle/10915/7510" rel="alternate"/>
<author>
<name>Ruiz, María Esperanza</name>
</author>
<author>
<name>Rubini, Agustina</name>
</author>
<author>
<name>Mandel, Sebastián J.</name>
</author>
<author>
<name>Volonté, María Guillermina</name>
</author>
<id>http://sedici.unlp.edu.ar:80/handle/10915/7510</id>
<updated>2012-05-03T01:50:21Z</updated>
<published>2007-01-01T00:00:00Z</published>
<summary type="text">Articulo
Pharmaceutical equivalence of Naproxen 500 mg tablets
Latin American Journal of Pharmacy; vol. 26, no. 4
El naproxeno (NP) es un antiinflamatorio no esteroideo (AINE), analgésico y antipirético, usado para el tratamiento de enfermedades reumáticas y procesos dolorosos inflamatorios agudos (mialgias, dismenorreas, etc). El objetivo del presente trabajo fue realizar un estudio comparativo de las nueve marcas de comprimidos conteniendo 500 mg de NP, presentes en el mercado farmacéutico argentino y aprobadas para su comercialización, con la finalidad de establecer equivalencia farmacéutica entre ellas. Se realizaron los siguientes ensayos: evaluación de rótulos y prospectos, descripción de los comprimidos, identidad y contenido de NP, uniformidad de unidades de dosificación, ensayo de disolución y perfiles de disolución. Se concluyó que no todas las especialidades medicinales conteniendo NP 500 mg, en su forma farmacéutica comprimidos, a la fecha del presente estudio, son equivalentes farmacéuticos.; Naproxen (NP) is a non-steroidal antiinflammatory drug, with analgesic and antipyretic activity, widely used to treat rheumatics diseases and acute painful process. The aim of this study was to compare the nine products, NP tablets 500 mg, which were available in the argentine pharmaceutical market, looking to the pharmaceutical equivalence between them. The following tests were made: evaluation of packaging specifications, description of tablets, identification and quantification, uniformity of dosage units, dissolution test and dissolution profiles. We conclude that there is not pharmaceutical equivalence between all the studied products at the moment of the present study.
</summary>
<dc:date>2007-01-01T00:00:00Z</dc:date>
<dc:description>El naproxeno (NP) es un antiinflamatorio no esteroideo (AINE), analgésico y antipirético, usado para el tratamiento de enfermedades reumáticas y procesos dolorosos inflamatorios agudos (mialgias, dismenorreas, etc). El objetivo del presente trabajo fue realizar un estudio comparativo de las nueve marcas de comprimidos conteniendo 500 mg de NP, presentes en el mercado farmacéutico argentino y aprobadas para su comercialización, con la finalidad de establecer equivalencia farmacéutica entre ellas. Se realizaron los siguientes ensayos: evaluación de rótulos y prospectos, descripción de los comprimidos, identidad y contenido de NP, uniformidad de unidades de dosificación, ensayo de disolución y perfiles de disolución. Se concluyó que no todas las especialidades medicinales conteniendo NP 500 mg, en su forma farmacéutica comprimidos, a la fecha del presente estudio, son equivalentes farmacéuticos.

Naproxen (NP) is a non-steroidal antiinflammatory drug, with analgesic and antipyretic activity, widely used to treat rheumatics diseases and acute painful process. The aim of this study was to compare the nine products, NP tablets 500 mg, which were available in the argentine pharmaceutical market, looking to the pharmaceutical equivalence between them. The following tests were made: evaluation of packaging specifications, description of tablets, identification and quantification, uniformity of dosage units, dissolution test and dissolution profiles. We conclude that there is not pharmaceutical equivalence between all the studied products at the moment of the present study.</dc:description>
</entry>
<entry>
<title>Morfoanatomia foliar e caulinar de dedaleiro: Lafoensia pacari A. St.-Hil. (Lythraceae)</title>
<link href="http://sedici.unlp.edu.ar:80/handle/10915/7509" rel="alternate"/>
<author>
<name>Mundo, Silvia Raquel</name>
</author>
<author>
<name>Duarte, Márcia do Rocio</name>
</author>
<id>http://sedici.unlp.edu.ar:80/handle/10915/7509</id>
<updated>2012-05-03T01:50:21Z</updated>
<published>2007-01-01T00:00:00Z</published>
<summary type="text">Articulo
Leaf and stem morpho-anatomy of dedaleiro: Lafoensia pacari A. St.-Hil. (Lythraceae)
Latin American Journal of Pharmacy; vol. 26, no. 3
Lafoensia pacari A. St.-Hil. é uma planta arbórea pertencente à família Lythraceae e conhecida vulgarmente como dedaleiro. É utilizada como febrífugo, cicatrizante e tônico na medicina popular. Este estudo teve como objetivo analisar a morfoanatomia de folha e caule da espécie com fins farmacognósticos. O material botânico foi fixado, seccionado e corado com azul de toluidina ou azul de astra-fucsina básica. Testes microquímicos usuais também foram realizados. As folhas são opostas, simples, simétricas e possuem forma oblongo-oboval. As células epidérmicas constituem um estrato único e, em vista frontal, apresentam contorno ondulado. Estômatos do tipo anomocítico ocorrem na face abaxial. O mesofilo é dorsiventral e a nervura principal, em secção transversal, é levemente côncava na face adaxial e nitidamente convexa na superfície oposta. Percorrendo o parênquima fundamental, há um feixe vascular bicolateral, em arco fechado e envolto por uma bainha esclerenquimática praticamente completa. O caule, em estrutura secundária inicial, é revestido por uma epiderme uniestratificada. O felogênio tem instalação periférica, o córtex é parenquimático e podem-se distinguir os cilindros floemáticos externo e interno limitando o xilema. A medula é constituída de células parenquimáticas, fibras e células pétreas. Células mucilaginosas e cristais de oxalato de cálcio estão presentes na folha e no caule.; Lafoensia pacari A. St.-Hil. is a woody plant which belongs to the family Lythraceae and is commonly known as dedadeiro. It is used as antipyretic, wound healing and tonic in folk medicine. This work has aimed to study the morpho-anatomy of the leaf and stem of this species for pharmacognostic purposes. The botanical material was fixed, sectioned and stained either with toluidine blue or astra blue-basic fuchsine. Standard microchemical tests were also carried out. The leaves are opposite, simple, symmetric and have oblong-obovate shape. The one-layered epidermal cells, in surface view, exhibit wavy contour. Anomocytic stomata occur on the abaxial side. The mesophyll is dorsiventral and the midrib, in cross-section, is slightly concave on the adaxial surface and evidently convex on the opposite side. Embedded in the ground parenchyma, there is a bicollateral vascular bundle, in close arc and encircled by a practically complete sclerenchymatic sheath. The stem, in initial secondary growth, has a uniseriate epidermis. The phellogen is formed superficially, the cortex is parenchymatic and it can be distinguish external and internal phloem cylinders bounding the xylem. The pith consists of parenchymatic cells, fibres and stone cells. Mucilaginous cells and calcium oxalate crystals are present in the leaf and stem.
</summary>
<dc:date>2007-01-01T00:00:00Z</dc:date>
<dc:description>Lafoensia pacari A. St.-Hil. é uma planta arbórea pertencente à família Lythraceae e conhecida vulgarmente como dedaleiro. É utilizada como febrífugo, cicatrizante e tônico na medicina popular. Este estudo teve como objetivo analisar a morfoanatomia de folha e caule da espécie com fins farmacognósticos. O material botânico foi fixado, seccionado e corado com azul de toluidina ou azul de astra-fucsina básica. Testes microquímicos usuais também foram realizados. As folhas são opostas, simples, simétricas e possuem forma oblongo-oboval. As células epidérmicas constituem um estrato único e, em vista frontal, apresentam contorno ondulado. Estômatos do tipo anomocítico ocorrem na face abaxial. O mesofilo é dorsiventral e a nervura principal, em secção transversal, é levemente côncava na face adaxial e nitidamente convexa na superfície oposta. Percorrendo o parênquima fundamental, há um feixe vascular bicolateral, em arco fechado e envolto por uma bainha esclerenquimática praticamente completa. O caule, em estrutura secundária inicial, é revestido por uma epiderme uniestratificada. O felogênio tem instalação periférica, o córtex é parenquimático e podem-se distinguir os cilindros floemáticos externo e interno limitando o xilema. A medula é constituída de células parenquimáticas, fibras e células pétreas. Células mucilaginosas e cristais de oxalato de cálcio estão presentes na folha e no caule.

Lafoensia pacari A. St.-Hil. is a woody plant which belongs to the family Lythraceae and is commonly known as dedadeiro. It is used as antipyretic, wound healing and tonic in folk medicine. This work has aimed to study the morpho-anatomy of the leaf and stem of this species for pharmacognostic purposes. The botanical material was fixed, sectioned and stained either with toluidine blue or astra blue-basic fuchsine. Standard microchemical tests were also carried out. The leaves are opposite, simple, symmetric and have oblong-obovate shape. The one-layered epidermal cells, in surface view, exhibit wavy contour. Anomocytic stomata occur on the abaxial side. The mesophyll is dorsiventral and the midrib, in cross-section, is slightly concave on the adaxial surface and evidently convex on the opposite side. Embedded in the ground parenchyma, there is a bicollateral vascular bundle, in close arc and encircled by a practically complete sclerenchymatic sheath. The stem, in initial secondary growth, has a uniseriate epidermis. The phellogen is formed superficially, the cortex is parenchymatic and it can be distinguish external and internal phloem cylinders bounding the xylem. The pith consists of parenchymatic cells, fibres and stone cells. Mucilaginous cells and calcium oxalate crystals are present in the leaf and stem.</dc:description>
</entry>
<entry>
<title>Influência da complexação com &amp;#946;-ciclodextrina sobre a liberação do acetato de dexametasona a partir de matrizes hidrofílicas de hidroxipropilmetilcelulose (HPMC) e polioxetileno (PEO)</title>
<link href="http://sedici.unlp.edu.ar:80/handle/10915/7508" rel="alternate"/>
<author>
<name>Fortunato, Keila A.</name>
</author>
<author>
<name>Doile, Mayara M.</name>
</author>
<author>
<name>Schmücker, Iara C.</name>
</author>
<author>
<name>Schucko, Sacha K.</name>
</author>
<author>
<name>Silva, Marcos A. S.</name>
</author>
<author>
<name>Rodrigues, Patrik O.</name>
</author>
<id>http://sedici.unlp.edu.ar:80/handle/10915/7508</id>
<updated>2012-05-03T01:50:21Z</updated>
<published>2007-01-01T00:00:00Z</published>
<summary type="text">Articulo
Influence of the complexation with &amp;#946;-cyclodextrin on dexamethasone acetate release from hydrophilic matrices of Hydroxypropylmethylcellulose (HPMC) and Polyethylene oxide (PEO)
Latin American Journal of Pharmacy; vol. 26, no. 4
O acetato de dexametasona (ADM), um fármaco de escassa solubilidade, foi incorporado em sua forma livre, complexada ou misturada fisicamente com &amp;#946;-ciclodextrina (&amp;#946;CD) em matrizes hidrofílicas de hidroxipropilmetilcelulose (HPMC) ou polioxetileno (PEO) em diferentes graus de viscosidade/peso molecular. A avaliação dos perfis de liberação in vitro indicou que as formulações mostraram-se eficazes na extensão da liberação do ADM, sendo a velocidade de liberação modificada como conseqüência da complexação. A aplicação de modelos matemáticos (zero ordem, Higuchi e Korsmeyer-Peppas) permitiu a caracterização da cinética de liberação, indicando que o método de complexação, polímero e viscosidade/peso molecular influenciaram os mecanismos pelos quais o fármaco foi liberado. Além disso, a equação de Weibull mostrou-se útil na diferenciação dos perfis de liberação de algumas formulações, quando os parâ- metros escala (&amp;#945;) e formato (&amp;#946;) foram avaliados; The dexamethasone acetate (DMA), a poorly water soluble drug, was incorporated alone, complexed or physically mixed with &amp;#946;-cyclodextrin (&amp;#946;CD), in hydrophilic matrix capsules containing hydroxypropyl methylcellulose (HPMC) or polyethylene oxide (PEO) in different viscosity/molecular weight. The evaluation of in vitro release profiles indicated that the formulations were effective in the extension of DMA release, being the release velocity modified due to complexation. The application of the mathematical models (zero order, Higuchi and Korsmeyer-Peppas) allowed the characterization of the release kinetics, indicating that the complexation method, polymer and viscosity/molecular weight influenced the mechanisms by which drug was released. Nevertheless, Weibull equation revealed to be useful in the differentiation of release profiles of some formulations, when the scale (&amp;#945;) and format (&amp;#946;) parameters were evaluated
</summary>
<dc:date>2007-01-01T00:00:00Z</dc:date>
<dc:description>O acetato de dexametasona (ADM), um fármaco de escassa solubilidade, foi incorporado em sua forma livre, complexada ou misturada fisicamente com &amp;#946;-ciclodextrina (&amp;#946;CD) em matrizes hidrofílicas de hidroxipropilmetilcelulose (HPMC) ou polioxetileno (PEO) em diferentes graus de viscosidade/peso molecular. A avaliação dos perfis de liberação in vitro indicou que as formulações mostraram-se eficazes na extensão da liberação do ADM, sendo a velocidade de liberação modificada como conseqüência da complexação. A aplicação de modelos matemáticos (zero ordem, Higuchi e Korsmeyer-Peppas) permitiu a caracterização da cinética de liberação, indicando que o método de complexação, polímero e viscosidade/peso molecular influenciaram os mecanismos pelos quais o fármaco foi liberado. Além disso, a equação de Weibull mostrou-se útil na diferenciação dos perfis de liberação de algumas formulações, quando os parâ- metros escala (&amp;#945;) e formato (&amp;#946;) foram avaliados

The dexamethasone acetate (DMA), a poorly water soluble drug, was incorporated alone, complexed or physically mixed with &amp;#946;-cyclodextrin (&amp;#946;CD), in hydrophilic matrix capsules containing hydroxypropyl methylcellulose (HPMC) or polyethylene oxide (PEO) in different viscosity/molecular weight. The evaluation of in vitro release profiles indicated that the formulations were effective in the extension of DMA release, being the release velocity modified due to complexation. The application of the mathematical models (zero order, Higuchi and Korsmeyer-Peppas) allowed the characterization of the release kinetics, indicating that the complexation method, polymer and viscosity/molecular weight influenced the mechanisms by which drug was released. Nevertheless, Weibull equation revealed to be useful in the differentiation of release profiles of some formulations, when the scale (&amp;#945;) and format (&amp;#946;) parameters were evaluated</dc:description>
</entry>
</feed>
